SCHEMBL17545980

SCHEMBL17545980

CN(c1ncnc2[nH]ncc12)[C@@H]1CCNC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 1/20 0.56
▸ AURKA O14965 1/20 0.56
▸ CSF1R P07333 2/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ BTK Q06187 2/20 0.44
▸ JAK3 P52333 8/20 0.44
▸ JAK1 P23458 5/20 0.44
▸ JAK2 O60674 1/20 0.43
▸ GRIN2B Q13224 1/20 0.42
▸ HPGDS O60760 1/20 0.42
▸ HTT P42858 1/20 0.41
▸ PDPK1 O15530 1/20 0.40
▸ RET P07949 1/20 0.40
▸ PI4KA P42356 1/20 0.40
▸ XDH P47989 1/20 0.40
▸ LRRK2 Q5S007 1/20 0.40
▸ PI4K2B Q8TCG2 1/20 0.40
▸ PI4K2A Q9BTU6 1/20 0.40
▸ PI4KB Q9UBF8 1/20 0.40
▸ AKT2 P31751 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17545975 1.00 CHEK1 (0.56) CHEK1AURKACSF1RL3MBTL1BTK
SCHEMBL17545876 0.92 CHEK1 (0.54) CHEK1AURKACSF1RL3MBTL1BTK
SCHEMBL17545887 0.92 CHEK1 (0.54) CHEK1AURKACSF1RL3MBTL1BTK
SCHEMBL2733906 0.91 CHEK1 (0.52) CHEK1AURKACSF1RL3MBTL1BTK
SCHEMBL28401502 0.84 JAK3 (0.52) CHEK1AURKACSF1RL3MBTL1BTK
SCHEMBL14347072 0.82 JAK3 (0.63) CHEK1AURKACSF1RL3MBTL1BTK
SCHEMBL20183448 0.79 JAK1 (0.71) JAK3JAK1JAK2
SCHEMBL20183439 0.79 JAK1 (0.71) JAK3JAK1JAK2
SCHEMBL20183438 0.79 JAK1 (0.71) JAK3JAK1JAK2
SCHEMBL31492342 0.75 CHEK2 (0.58) CHEK1L3MBTL1JAK3JAK1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9273028-B2 Heterocyclic tyrosine kinase inhibitors BIOGEN MA INC. (US) 2016-03-01 — — US disclosed
US-9273028-B2 Heterocyclic tyrosine kinase inhibitors BIOGEN MA INC. (US) 2016-03-01 — — US disclosed
Send feedback